Asset profile
RGX-202
Gene therapy / editing
Evidence outlook · registrational
Duchenne Muscular Dystrophy: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. The registry's posted readout date (2026-09) has passed without a status update. Check News for topline announcements.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
3 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 3 same-indication; 1 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| RGX-202: this drug | Phase 2/3 | Gene therapy / editing | — | ||
| Deramiocel (CAP-1002) | Phase 3 | Cell therapy | Cardiac cell therapy | ||
| BMN 351 | Phase 1/2 | RNA / oligonucleotide | — | ||
| WVE-N531 | Phase 1/2 | RNA / oligonucleotide | — |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.